InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$18.60+0.25 (+1.36%)
Close on Nov 13, 2026Market cap $102.18MP/E –Yield –
InMed Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
InMed Pharmaceuticals's cash was $1.10M at Sep 30, 2026. For fiscal 2026 it was $2.20M, down 80.2% from the year before. The highest annual figure on record is $11.10M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $2.20M | -80.2% |
| FY2025 | Jun 30, 2025 | $11.10M | +68.2% |
| FY2024 | Jun 30, 2024 | $6.60M | -26.3% |
| FY2023 | Jun 30, 2023 | $8.96M | +44.0% |
| FY2022 | Jun 30, 2022 | $6.22M | -16.0% |
| FY2021 | Jun 30, 2021 | $7.41M | +26.7% |
| FY2020 | Jun 30, 2020 | $5.85M | -40.6% |
| FY2019 | Jul 1, 2019 | $9.84M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $1.10M | -88.3% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $2.20M | -80.2% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $5.20M | +10.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $7.00M | +100.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $9.40M | +67.9% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $11.10M | +68.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $4.70M | -38.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $3.50M | -63.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $5.60M | -17.6% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $6.60M | -26.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $7.60M | -21.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $9.50M | -17.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $6.80M | -27.6% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $8.96M | +44.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $9.65M | +62.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $11.50M | +1.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $9.39M | -39.0% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $6.22M | -16.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $5.94M | -37.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $11.33M | +12.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $15.39M | +238.9% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $7.41M | +26.7% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $9.50M | +36.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $10.07M | +9.4% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $4.54M | -58.8% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $5.85M | -40.6% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $6.97M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $9.20M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $11.01M | – |
| Q4 FY2019CQ2 2019 | Jul 1, 2019 | $9.84M | – |
See a number that looks wrong?